Glow-in-the-Dark drug could help surgeons spot brain cancer
NCT ID NCT07210632
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This early-phase trial tests a special version of the immunotherapy drug nivolumab that has a fluorescent dye attached (nivo800). The dye makes the drug glow under near-infrared light, allowing researchers to see exactly where the drug goes in the tumor during surgery. About 38 adults with suspected high-grade glioma will receive a single infusion before their planned tumor removal. The main goal is to check safety and find the best dose for imaging, not to treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab-IRDye800 (nivo800)
- What this could lead to
- If successful, this could improve surgeons' ability to see tumor tissue during operations, potentially leading to more complete removal of high-grade gliomas.
- What could go wrong
- This is a very early, small safety and imaging study (38 participants). It is not designed to test whether the drug treats the tumor, and the imaging benefit may not translate into better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?